BMG Pharma launches NormAdvance, the complete solution for the management of acne
BMG Pharma is pleased to announce the launch of NormAdvance™, an innovative new 3-product kit to manage the symptoms of mild to moderate acne. The product will be marketed in Italy via NormAdvance™ retail website.
Marco Mastrodonato, CEO of BMG Pharma commented: “85% of Acne patients have mild to moderate acne and initially do not visit a dermatologist for treatment but seek self-medication. Currently, there is no such complete efficacious treatment available on the EU market which covers these patients’ requirements.”
NormAdvance is a comprehensive kit of 3 modern products, based on a unique combination of ingredients with clinical data proving efficacy.
This trio of products cleanses, moisturizes and manages acne-prone skin. In addition, it is as effective as Benzoyl peroxide while unlike the latter, can be used during summer, since it is proven to be non-photosensitizing; allowing a seamless continued treatment and improved clinical results due to better patient compliance.
A clinical study performed on 120 male and female patients, aged 14 to 40 years old to compare the safety and effectiveness of a hydrogen peroxide-based acne regimen (NormAdvance™, BMG Pharma) to a benzoyl peroxide based regimen, showed outstanding and in some cases better results for NormAdvance™ in terms of efficacy, compatibility, improvement of the skin over time, tolerability and pleasantness.
For more product information please visit NormAdvance™ website.
About BMG Pharma S.p.A.
BMG Pharma S.p.A. is a specialty biotech pharmaceutical company with its head office in Milan, Italy, leveraging its proprietary technology platform in the hyaluronan and glycosaminoglycans to develop products that address unmet needs for patients in Dermatology, Oral Care and Osteoarthritis. BMG Pharma S.p.A. is dedicated to helping pharmaceutical companies in providing valuable and innovative products to patients, pharmacists, and physicians.